

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

### **CLARIFICATION ANNOUNCEMENT**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) on a voluntary basis. Reference is made to the announcements (the “**Announcements**”) of the Company dated January 29 and February 4, 2024 in relation to the Draft Bill that was recently introduced in the U.S. House of Representatives. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has noted that a procedural hearing in relation to, among others, a revised draft bill was held by the U.S. Senate on March 6, 2024. The Company would like to reiterate that it is not a subsidiary of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) and operates its business independently. As a global biologics CRDMO platform, the Company does not have a human genomics business, nor does it collect human genomic data in any of its businesses. Further, the Company would like to reiterate that it does not pose any national security risk to the U.S. or any other countries.

As the revised draft bill remains subject to further review and modification by U.S. legislators and has not been enacted into law, the Company will continue to work closely with its advisors to monitor the legislative process for the revised draft bill.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, March 7, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

\* *For identification purpose only*